Table 2.

Univariate and multivariate analyses of prognostic factors for overall survival and disease-free survival of HCC patients in the study cohort

Variable	OS				DFS
	Univariate		Multivariate		Univariate		Multivariate
	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p
Age
≥60 years	0.87 (0.46–1.66)	0.672			0.69 (0.41–1.15)	0.154
Gender
Female	0.83 (0.36–1.89)	0.655			1.28 (0.61–2.70)	0.515
HBsAg
Yes	0.83 (0.36–1.89)	0.655			1.13 (0.56–2.30)	0.732
AFP (ng/mL)
≥ 400	1.56 (0.81–2.99)	0.182			1.16 (0.68–1.98)	0.581
Liver cirrhosis
Yes	1.25 (0.65–2.40)	0.496			1.44 (0.86–2.43)	0.166
Tumor size
≥5 cm	2.33 (1.22–4.46)	0.010	1.65 (0.81–3.37)	0.169	2.22 (1.33–3.71)	0.002	1.95 (1.11–3.43)	0.021
Tumor number
Multiple	1.04 (0.37–2.93)	0.943			1.66 (0.79–3.51)	0.182
Tumor differentiation
Poorly	1.30 (0.68–2.47)	0.433			0.89 (0.54–1.49)	0.668
Tumor thrombi
Yes	2.31 (1.05–5.05)	0.037	1.69 (0.70–4.12)	0.246	3.68 (1.94–7.01)	<0.001	3.50 (1.75–6.99)	<0.001
TNM stage
III +  IV	3.48 (1.52–7.99)	0.003	2.73 (0.96–7.77)	0.059	3.12 (1.47–6.62)	0.003	1.91 (0.77–4.72)	0.161
Group
High	2.38 (1.17–4.81)	0.016	2.66 (1.28–5.55)	0.009	1.76 (1.03–3.01)	0.037	1.98 (1.13–3.47)	0.017

HCC hepatocellular carcinoma, OS overall survival, DFS disease-free survial, HBsAg hepatitis B surface antigen, AFP α-fetoprotein, TNM tumor node metastasis, HR hazard risk ratio, CI confidence interval